Loading
No insider purchase over the last 90 days. The latest was filed 04 Dec 2025.
Standard Biotools Inc.: what insiders have been doing
Standard Biotools Inc., classified in the Energy sector, is a listed company based in South San Francisco, United States, founded in 1999. Its insiders report their share dealings to SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 31 filings came from 9 insiders.
Every open-market trade in the period is a purchase: 5 purchases worth €1.3M, from 1 insider, and not a single sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 1 senior executive among the declarants. Biggest ticket of the year: €467k, bought by Casdin Partners Master Fund, L.P. and made public on 17 November 2025.
The latest purchase dates back some time: it was published 318 days ago, on 4 December 2025. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
Compared with its exchange (5,458 companies, median 22 filings), a count of 31 filings is above the norm. Since 2021, the database holds 32 purchases and 6 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 85.3 m USD and net income of -74.9 m USD.
In the same sector, recent insider purchases at RGC Resources Inc and Empire Petroleum Corp also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
174
Thresholds
n/a
Buy Volume
€19M
32 ops. · all time
Sell Volume
€34,197
6 ops. · all time
Who traded when
BuySaleCasdin Partners Master Fund, L.P.10 buys
Hanjoon Alex Kim2 sales
Michael Egholm2 sales
Sean Mackay2 sales
Since the insiders bought
- -28.7%Entry US$1.43 · Close at T+90 US$1.02
- +17.6%Entry US$2.04 · Close at T+365 US$2.40
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,579 of 24,148 companies
18.1
score / 100
Value7
Quality29
FCF yld-33%
Earn yld-30%
EV/EBITDA·
ROE-11%
Gross mgn50%
Net mgn-88%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.63
Analyst consensus
1 analysts3.00/5
US$1.35Target US$1.35(+115%)US$1.35
Income statement
RevenueUS$85.3M
Gross profitUS$42.5M50% margin
EBITDA-US$85.7M-100% margin
Net income-US$74.9M100.4% margin
Valuation
PER (trailing)20.9x
PER (forward)-80.0x
P/Book0.5x
Beta1.35
Balance sheet & cash
Market capUS$246.9M
Total debtUS$30.8M
Free Cash Flow-US$82.6M
Debt / Equity5%
Profitability & ownership
ROE-11.2%
ROA-6.6%
% insiders1.8%
% institutions75.8%
Last declaration on 24 August 2026
Declarations174 total
97,627 shares@ US$0.6720.022% mcap5.5% of flowCommon StockSEC:0001193125-26-363758:0
28,195 shares@ US$0.6720.0063% mcap6.7% of flowCommon StockSEC:0001193125-26-363762:0
25,729 shares@ US$0.6720.0058% mcap12.0% of flowCommon StockSEC:0001193125-26-363767:0
362,625 shares@ US$0.8680.11% mcap26.7% of flowCommon StockSEC:0001193125-26-333225:0
202,476 shares@ US$0.8950.062% mcap65.3% of flowCommon StockSEC:0001193125-26-318442:0
99,116 sharesCommon StockSEC:0001193125-26-279834:0
99,116 sharesCommon StockSEC:0001193125-26-279828:0
99,116 sharesCommon StockSEC:0001193125-26-279824:0
99,116 sharesCommon StockSEC:0001193125-26-279823:0
95,014 shares@ US$0.9087.3% of flowCommon StockSEC:0001193125-26-148615:2
21,301 shares@ US$0.9086.9% of flowCommon StockSEC:0001193125-26-148613:2
1,042,373 shares0Common StockSEC:0001193125-26-148615:0
196,513 shares0Common StockSEC:0001193125-26-148615:1
323,173 shares0Common StockSEC:0001193125-26-148613:0
70,183 shares0Common StockSEC:0001193125-26-148613:1
272,107 shares0Common StockSEC:0001193125-26-148614:0
51,282 shares@ US$1.1746.8% of flowCommon StockSEC:0001193125-26-086154:0
52,991 shares@ US$1.179.7% of flowCommon StockSEC:0001193125-26-086197:0
66,127 shares@ US$1.156.3% of flowCommon StockSEC:0001193125-26-067641:0
19,661 shares@ US$1.1515.5% of flowCommon StockSEC:0001193125-26-067638:0
12,740 shares@ US$1.155.1% of flowCommon StockSEC:0001193125-26-067636:0
125,000 shares@ US$1.42010.2% of flowCommon Stock, $0.001 par value per shareSEC:0000919574-25-007243:0
Canonical exit: 2 Mar 2026 (T+90)
150,000 shares@ US$1.43250.2% of flowCommon Stock, $0.001 par value per shareSEC:0000919574-25-007187:0
Canonical exit: 22 Feb 2026 (T+90)
25 of 174 declarations
About Standard Biotools Inc.
Standard Biotools Inc. is a company focused on the energy sector, providing innovative solutions for sustainable development. It is listed on the XNAS market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
